News | Women's Health | January 02, 2018

Research explores implications of long-term effects of chemotherapy and radiation

Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers

January 2, 2018 — A new study found women who had received chemotherapy and/or radiation therapy to treat breast cancer were more likely to have high levels of DNA damage and reduced activity of an enzyme involved in chromosome healing, compared to women who underwent surgery alone. The results suggest that some breast cancer survivors may be more vulnerable to biological changes associated with accelerated aging because of their prior treatment.  

Advances in cancer screening and treatment have resulted in a growing number of cancer survivors in the United States. In many ways, cancer survivors appear "older" than people of similar age without a history of cancer. These "late effects" of cancer treatment are suspected to be the result of accelerated aging at the biological level.

Radiation therapy and chemotherapy are highly effective treatments for cancer, but can also be toxic to healthy immune cells. Like other kinds of cells, immune cells accumulate damage to DNA as they age, which can impact their ability to divide in response to pathogens. When the cell stops dividing it enters a state referred to as cellular senescence. Senescent cells are a key player in the aging process. They often have shortened telomeres, a marker of the cells age, and low telomerase activity, an enzyme that protects chromosomal ends.

Little is known about whether prior exposure to these treatments is related to these "markers" of cellular aging that can appear years later in breast cancer survivors. The study examined whether past exposure to chemotherapy and/or radiation is related to these markers, including DNA damage, telomerase activity and telomere length in breast cancer survivors following treatment. In addition, the researchers analyzed DNA damage and lower telomerase activity in association with elevations in inflammatory activity, which is another known indicator of biological aging.

The University of California Los Angeles (UCLA) team assessed 94 women, at three to six years after completion of primary treatment for breast cancer. The researchers discovered that those who had been exposed to chemotherapy and/or radiation showed elevated levels of DNA damage in blood cells, and lower telomerase enzymatic activity, compared to women who had previously received surgery alone. They found no differences in telomere length between the two groups of women, however. The results also showed longer-term increases in DNA damage and reductions in telomerase activity that coincide with higher levels of inflammatory activation.  

The potential for long-term impact of radiation and chemotherapy on the health and quality of life for cancer survivors is of increasing concern, especially as they are surviving much longer. In particular, these treatments may have a lasting effect on the rate of aging in various tissues in the body. These biological findings in breast cancer survivors who have received chemotherapy and/or radiation suggest that they may be at greater risk for accelerated aging than those who received surgery alone. Research focused on understanding the biology of treatment effects on aging pathways may lead to the development of future strategies to prevent these changes in cancer survivors.

The research is published online in NPJ Breast Cancer, a part of the Nature Partner Journals series.

For more information: www.nature.com/npjbcancer


Related Content

News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
Subscribe Now